Both EGFR and ErbB2 have been established as clinically relevant drug targets, and the therapeutic antibodies trastuzumab, cetuximab and panitumumab, as well as the tyrosine kinase inhibitor erlotinib, gefitinib and lapatinib, are currently used in the therapy of adult patients with breast, gastric, colorectal, head and neck, lung, or pancreatic cancer [5], [41]. Here, EGFR is linked to pancreatic neoplasm.